(Q38782719)

6 September 2017

A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas (English)

1 reference

6 September 2017

phase II clinical trial

0 references

author name string

Priya Kumthekar

1

1 reference

6 September 2017

Sean Grimm

2

1 reference

6 September 2017

James Chandler

3

1 reference

6 September 2017

Minesh Mehta

4

1 reference

6 September 2017

Maryanne Marymont

5

1 reference

6 September 2017

Robert Levy

6

1 reference

6 September 2017

Kenji Muro

7

1 reference

6 September 2017

Irene Helenowski

8

1 reference

6 September 2017

Katie McCarthy

9

1 reference

6 September 2017

Leanne Fountas

10

1 reference

6 September 2017

Jeffrey Raizer

11

1 reference

6 September 2017

16 May 2017

1 reference

Journal of Neuro-Oncology

6 September 2017

1 reference

6 September 2017

133

1 reference

6 September 2017

3

1 reference

6 September 2017

589-594

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-017-2469-x

6 September 2017

0 references

cites work

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

Understanding the role of tumor stem cells in glioblastoma multiforme: a review article

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

Radiotherapy and temozolomide for anaplastic astrocytic gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

Arsenic reverses glioblastoma resistance to mTOR-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2469-X

Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28510787

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Bevacizumab for newly diagnosed glioblastoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28510787

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Mechanisms of action of arsenic trioxide.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28510787

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-017-2469-X

1 reference

Dimensions Publication ID

6 September 2017

0 references

1 reference